Pharma Biotech Expo Market Analysis and Reports | USA Conference Series

Market Analysis - Pharma Biotech Expo 2018

 The pharmaceutical sector has consistently been one of the most R&D intensive industries in the United States. The research-based industry generally allocates around 15 to 20 percent of revenues to R&D activities and invests over $50 billion on R&D annually. Although the United States remains the global leader in innovative R&D investment, producing more than half the world’s new molecules in the last decade, R&D performed in the United States has become increasingly expensive relative to emerging economies in Asia, such as China and Singapore.

Integrated research ecosystem enables companies to access multidisciplinary capabilities in a single location, which improves R&D decision-making and accelerates drug discovery and development. More than 30 world’s leading biomedical sciences companies (including GlaxoSmithKline, Novartis and Takeda) are leveraging to drive innovation, growing the nation’s biotechnology and pharmaceutical industry by more than 30 percent.

Biomedical engineering involves applying engineering principles to biology, medicine and healthcare to solve problems. It is a fast-growing area of engineering and individuals would typically find themselves working in health services, the medical devices industry/ research. The global medical devices market alone is estimated to be worth USD $381billions, and America accounts for around 45% of the global market.

The worldwide market for pharmaceuticals is projected to grow from $1 trillion in 2015 to $1.3 trillion by 2020, with compound annual growth rate of 4.9%. Pharmaceutical and biotechnology industries are significantly investing in R&D in the recent year owing to rising demand for advanced medicines. This may be attributed to increasing aging population, incidence of chronic diseases, and communicable diseases.